---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-005585"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T06:35:10.280719+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MyMD raises $15M in registered direct offering of convertible preferred stock and warrants

## Summary
- Gross proceeds of $15M from sale of Series F Convertible Preferred Stock and warrants to accredited/institutional investors.
- Conversion/exercise price of $2.255 per share, ~10% premium to Feb 17 closing price.
- Warrants exercisable immediately at $2.255, expire in 5 years; preferred stock convertible at same price.
- Proceeds to fund development of MYMD-1 for sarcopenia (Phase 2) and rheumatoid arthritis.
- Closing expected Feb 23, 2023; Katalyst Securities as placement agent.

## SEC filing metadata
- accession: 0001493152-23-005585
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315223005585/0001493152-23-005585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315223005585/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-005585
- JSON: https://secwatch.observer/filing/0001493152-23-005585.json
- Plain text: https://secwatch.observer/filing/0001493152-23-005585.txt

## Key facts
- Material Agreements
  Q/C TECHNOLOGIES, INC. entered into Engagement Letter with Katalyst Securities LLC valued at 6% of the gross proceeds.
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Katalyst Securities LLC
  - Value: 6% of the gross proceeds
  source text: In connection with the Offering, pursuant to an Engagement Letter (the “Engagement Letter”), between the Company and Katalyst Securities LLC (the “Placement Agent”), the Company has agreed to pay the Placement Agent a cash fee equal to 6% of the gross proceeds from any sale of securities in the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321834/000149315223005585/0001493152-23-005585-index.htm
- Material Agreements
  Q/C TECHNOLOGIES, INC. entered into Securities Purchase Agreement with certain accredited investors valued at $15 million (effective 2023-02-21).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: $15 million
  - Effective: 2023-02-21
  source text: On February 21, 2023, MyMD Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell to the Investors in a registered direct offering (the “Offering”) (i) an aggregate of 15,000 shares of the Company’s newly-designated Series F Convertible Preferred Stock with a stated value of $1,000 per share, initially convertible into up to 6,651,885 shares of the Company’s common stock, no par value (the “Common Stock”), at a conversion price of $2.255 per share (the “Preferred Shares”), and (ii) warrants to acquire up to an aggregate of 6,651,885 shares of Common Stock (the “Warrants”). The closing of the Offering is expected to occur on February 23, 2023, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds from the Offering are expected to be $15 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321834/000149315223005585/0001493152-23-005585-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.